Previous 10 | Next 10 |
Program aimed to deliver early-stage clinical supply of plasmid DNA for drug substance manufacturing Charles River Laboratories International, Inc. (NYSE: CRL) and Ziphius Vaccines, a biopharmaceutical company developing self-amplifying RNA (saRNA) based medicinal products f...
Ariel Investments’ 13F portfolio value decreased from $11.86B to $11.27B this quarter. They increased Gentex, Resideo Technologies, and Boyd Gaming while reducing Progressive Corp and Berkshire Hathaway. The top three positions are Madison Square Garden Entertainment, Matte...
CRL is a high-quality business that operates quietly and unnoticed in the background. It has consistently grown revenue, earnings and free cash flow over the years. One can think of CRL as a royalty on the growth of others (e.g. healthcare and biotech companies, governments, acade...
Citing the recent challenges in the patient enrollment, the pharmacy chain operator Walgreens Boots Alliance (NASDAQ:WBA) announced the launch of its clinical trial business on Thursday to expedite the drug development process. Arguing that COVID-19 has exacerbated the difficulties in patient...
Billionaire wildcatter Howard Hamm's $70/share bid for the remainder of Continental Resources (NYSE:CLR) he doesn't already own is likely not a large enough price for the shale driller, according to analysts. CLR shares rose 15%, trading at $73.60, indicating that some investors bel...
Charles River Laboratories International (NYSE:CRL) and privately-held pharma company ASC Therapeutics on Monday said they had agreed to make second-generation gene therapy ASC618 for the treatment of hemophilia A. Hemophilia A is caused due to a mutation in the F8 gene, which provides i...
Expanded relationship will build upon established processes initiated in 2019 to meet ASC Therapeutics clinical program Charles River Laboratories International, Inc. (NYSE: CRL) and ASC Therapeutics, a privately held biopharmaceutical company pioneering the development of t...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock valuations are collapsing while earnings are improving, according to Credit Suisse. "While the median company has seen their stock price fall -24.4% since its peak, the median P/E multiple fell -27.5%," strategist Jonathan Golub wrote in a note. "This difference is explained by a health...
Inotiv has largely focused on pre-clinical services that is performed prior to the initiation of any clinical trials in humans. NOTV’s revenue declined by 38% from 2011-2016 and EBITDA turned negative in 2016. Revenue has grown significantly from $20mm in FY ’16 to a...
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Clinical trials for AAV9 gene therapy bolstered with plasmid and viral vector CDMO expertise Charles River Laboratories International, Inc. (NYSE: CRL) announced today a collaboration with the FOXG1 Research Foundation (FRF) highlighting the patient advocacy group’s model t...
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...